Clinical Trials

Sponsor: Replimune

Sponsor Study ID: RPL-001-16

Study Title: An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination with PD1 Blockade in Patients with Solid Tumors (IGNYTE)

NCT Number: NCT03767348

Phase: I/II

Protocol Type: Treatment

Age Group: Adult

Disease Sites: Other Skin

Study Objectives: RPL-001-16 is a Phase 1/2, open label, dose escalation and expansion clinical study of RP1 alone and in combination with nivolumab in adult subjects with advanced and/or refractory solid tumors, to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), as well as to evaluate preliminary efficacy.

If you would like to contact a MUSC study team member to learn more information about this study, click HERE.